Appraising research policy instrument mixes: a multicriteria mapping study in six European countries of diagnostic innovation to manage antimicrobial resistance.

Antimicrobial resistance Diagnostic innovation Foresight appraisal Multicriteria mapping Policy evaluation Policy instrument mixes

Journal

Research policy
ISSN: 0048-7333
Titre abrégé: Res Policy
Pays: Netherlands
ID NLM: 0333524

Informations de publication

Date de publication:
May 2021
Historique:
entrez: 4 5 2021
pubmed: 5 5 2021
medline: 5 5 2021
Statut: ppublish

Résumé

This article provides prospective appraisal of key policy instruments intended to stimulate innovation to combat antimicrobial resistance (AMR). AMR refers to the ability of microbes to evolve resistance to those treatments designed to kill them, and is associated with the overuse or misuse of medicines such as antibiotics. AMR is an emerging global challenge with major implications for healthcare and society as a whole. Diagnostic tests for infectious diseases can guide decision making when prescribing medicines, so reducing inappropriate drug use. In the context of growing international interest in policies to stimulate innovation in AMR diagnostics, this study uses multicriteria mapping (MCM) to appraise a range of policy instruments in order to understand their potential performance while also highlighting the uncertainties that stakeholders hold about such interventions in complex contexts. A contribution of the article is the demonstration of a novel method to analyse and visualise MCM data in order to reveal stakeholder inclinations towards particular options while exploring interviewees' uncertainties about the effectiveness of each instrument's design or implementation. The article reports results from six European countries (Germany, Greece, Italy, the Netherlands, Spain and the UK). The findings reveal which policy instruments are deemed most likely to perform well, and why, across stakeholder groups and national settings, with areas of common ground and difference being identified. Importantly, the conclusions presented here differ from prominent policy discourse, with international implications for the design of mixes of policy instruments to combat AMR. Strategic and practical methodological implications also emerge for general appraisal of innovation policy instrument mixes.

Identifiants

pubmed: 33941992
doi: 10.1016/j.respol.2020.104140
pii: S0048-7333(20)30215-8
pmc: PMC8039188
doi:

Types de publication

Journal Article

Langues

eng

Pagination

104140

Subventions

Organisme : Medical Research Council
ID : MR/N014316/1
Pays : United Kingdom

Informations de copyright

© 2020 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

PLoS Med. 2005 Aug;2(8):e124
pubmed: 16060722
J Nanopart Res. 2010 Aug;12(6):1959-1970
pubmed: 21170118
Health Syst Transit. 2014;16(4):1-168
pubmed: 25471543
Lancet. 2005 Feb 12-18;365(9459):579-87
pubmed: 15708101
Health Syst Transit. 2010;12(4):1-295, xix-xx
pubmed: 21224176
Nature. 2004 Oct 21;431(7011):883
pubmed: 15496877
Nat Rev Drug Discov. 2006 Jun;5(6):463-9
pubmed: 16718275
J Hosp Infect. 2019 Apr;101(4):426-427
pubmed: 30826342
Psychol Sci. 2014 Jan;25(1):7-29
pubmed: 24220629
Health Syst Transit. 2016 Mar;18(2):1-240
pubmed: 27467715
BMJ. 2013 Mar 11;346:f1493
pubmed: 23479660
Health Technol Assess. 1998;2(16):iii-ix, 1-274
pubmed: 9919458
Sustain Sci. 2017;12(4):579-596
pubmed: 30147759
Obes Rev. 2007 May;8 Suppl 2:17-27
pubmed: 17371304
Int J Epidemiol. 2013 Aug;42(4):1012-4
pubmed: 24062287
Lancet Infect Dis. 2016 Feb;16(2):239-51
pubmed: 26795692
Lancet Infect Dis. 2016 Apr;16(4):431-40
pubmed: 26708524
Nature. 2010 Dec 23;468(7327):1029-31
pubmed: 21179144
Health Policy. 2017 Oct;121(10):1025-1030
pubmed: 28888660
Health Syst Transit. 2015;17(5):1-126
pubmed: 27049966
Nature. 2015 Dec 3;528(7580):S50-2
pubmed: 26633765
Health Syst Transit. 2014;16(2):1-296, xxi
pubmed: 25115137
Lancet Planet Health. 2018 Sep;2(9):e398-e405
pubmed: 30177008
Clin Infect Dis. 2011 May;52 Suppl 5:S397-428
pubmed: 21474585
BMC Infect Dis. 2014 Jan 09;14:13
pubmed: 24405683

Auteurs

Josie Coburn (J)

Science Policy Research Unit, University of Sussex Business School, University of Sussex, Falmer, Brighton, United Kingdom.

Frederique Bone (F)

Science Policy Research Unit, University of Sussex Business School, University of Sussex, Falmer, Brighton, United Kingdom.

Michael M Hopkins (MM)

Science Policy Research Unit, University of Sussex Business School, University of Sussex, Falmer, Brighton, United Kingdom.

Andy Stirling (A)

Science Policy Research Unit, University of Sussex Business School, University of Sussex, Falmer, Brighton, United Kingdom.

Jorge Mestre-Ferrandiz (J)

Visiting Fellow, Office of Health Economics, London, United Kingdom.

Stathis Arapostathis (S)

Department of History and Philosophy of Science, National and Kapodistrian University of Athens, Athens, Greece.

Martin J Llewelyn (MJ)

Brighton and Sussex Medical School, Falmer, Brighton, United Kingdom.

Classifications MeSH